Development
Lexicon Pharmaceuticals, Inc.
LXRX
$1.15
$0.109.52%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -157.86M | -130.72M | -110.40M | -101.94M | -97.06M |
| Total Depreciation and Amortization | 510.00K | 467.00K | 430.00K | 427.00K | 436.00K |
| Total Amortization of Deferred Charges | 1.50M | 1.10M | 981.00K | 741.00K | 404.00K |
| Total Other Non-Cash Items | 10.79M | 13.15M | 12.17M | 11.52M | 10.53M |
| Change in Net Operating Assets | 12.14M | 5.27M | -218.00K | 402.00K | -4.42M |
| Cash from Operations | -132.92M | -110.74M | -97.04M | -88.85M | -90.11M |
| Capital Expenditure | -1.72M | -1.64M | -1.50M | -1.33M | -103.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -75.95M | -113.90M | -53.08M | -69.75M | -89.05M |
| Cash from Investing | -77.67M | -115.54M | -54.58M | -71.08M | -89.16M |
| Total Debt Issued | 74.93M | 74.68M | 24.72M | 48.87M | 23.90M |
| Total Debt Repaid | -- | -- | -- | -- | -11.70M |
| Issuance of Common Stock | 139.03M | 233.30M | 94.27M | 94.27M | 94.65M |
| Repurchase of Common Stock | -1.10M | -887.00K | -887.00K | -927.00K | -864.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 212.87M | 307.10M | 118.10M | 142.21M | 105.98M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.28M | 80.82M | -33.52M | -17.72M | -73.28M |